3,584 IDEXX Laboratories, Inc. $IDXX Shares Purchased by ProShare Advisors LLC

Posted by Brenda Bartman on Nov 2nd, 2026

ProShare Advisors LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 3.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,635 shares of the company’s stock after acquiring an additional 3,584 shares during the quarter. ProShare Advisors LLC’s holdings in IDEXX Laboratories were worth $50,984,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. MGO One Seven LLC increased its position in shares of IDEXX Laboratories by 288.1% during the third quarter. MGO One Seven LLC now owns 5,566 shares of the company’s stock worth $2,907,000 after purchasing an additional 4,132 shares in the last quarter. CFC Planning Co LLC boosted its position in shares of IDEXX Laboratories by 24.7% in the 3rd quarter. CFC Planning Co LLC now owns 2,953 shares of the company’s stock valued at $1,543,000 after purchasing an additional 584 shares during the period. International Assets Investment Management LLC grew its stake in IDEXX Laboratories by 30,484.1% during the 3rd quarter. International Assets Investment Management LLC now owns 234,274 shares of the company’s stock worth $122,336,000 after buying an additional 233,508 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al grew its stake in IDEXX Laboratories by 36.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 126,164 shares of the company’s stock worth $65,882,000 after buying an additional 33,946 shares during the last quarter. Finally, Crystal Rock Capital Management increased its position in IDEXX Laboratories by 6.4% during the third quarter. Crystal Rock Capital Management now owns 11,275 shares of the company’s stock worth $5,888,000 after buying an additional 675 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on IDXX shares. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. KeyCorp initiated coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating on the stock. JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday, October 16th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, BTIG Research dropped coverage on shares of IDEXX Laboratories in a research note on Friday. They set a “buy” rating for the company. Eight investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $721.67.

Read Our Latest Report on IDEXX Laboratories

IDEXX Laboratories Price Performance

IDXX opened at $551.21 on Monday. The business has a 50 day moving average price of $534.27 and a two-hundred day moving average price of $574.09. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The company has a market cap of $43.42 billion, a PE ratio of 38.76 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.23. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.